Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability

NCT05721898 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 394

Last updated 2023-11-01

No results posted yet for this study

Summary

Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue leading to bone fragility (i.e., weakness) and an increased risk for fracture. Bone strength is a critical factor in a bone's ability to resist fracture and is clearly an important outcome in studies of osteoporosis. The current standard for assessing bone health and diagnosing osteoporosis is to use dual-energy x-ray absorptiometry (DXA) to quantify the areal bone mineral density (BMD), typically at the hip and spine. However, DXA-derived BMD has limited discriminatory accuracy for distinguishing individuals that experience fragility fracture from those who do not. One well known limitation of DXA-derived BMD is that it does not adequately assay bone strength. There is a critical unmet need to identify persons more accurately with diminished bone strength who are at high risk of experiencing a fragility fracture in order to determine an appropriate therapy. A potential new diagnostic approach to assess skeletal health and improve osteoporosis diagnosis is the use of Cortical Bone Mechanics Technology (CBMT). CBMT leverages multifrequency vibration analysis to conduct a noninvasive, dynamic 3-point bending test that makes direct, mechanical measurements of ulnar cortical bone. Data indicates that CBMT-derived ulnar flexural rigidity accurately estimates ulnar whole bone strength and provides information about cortical bone that is unique and independent of DXA-derived BMD. However, the clinical utility of CBMT-derived flexural rigidity has not yet been demonstrated. The investigators have designed a clinical study to assess the accuracy of CBMT-derived ulnar flexural rigidity in discriminating post-menopausal women who have suffered a fragility fracture from those who have not. These data will be compared to DXA-derived peripheral and central measures of BMD obtained from the same subjects.

Conditions

  • Osteoporosis
  • Osteopenia or Osteoporosis
  • Osteoporosis, Postmenopausal
  • Osteoporosis Risk
  • Osteoporotic Fractures
  • Fragility Fracture
  • Bone Fracture

Interventions

DIAGNOSTIC_TEST

Cortical Bone Mechanics Technology

Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.

Sponsors & Collaborators

  • Indiana University School of Medicine

    collaborator OTHER
  • University of Florida

    collaborator OTHER
  • University of South Florida

    collaborator OTHER
  • Ohio University

    lead OTHER

Principal Investigators

  • Brian Clark, PhD · Ohio Musculoskeletal and Neurological Institute (OMNI) at Ohio University

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-10-30
Completion
2023-10-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05721898 on ClinicalTrials.gov